Ranbaxy consolidates presence in dermatology
Ranbaxy Laboratories Limited (Ranbaxy), announced that it has acquired trademarks, product dossiers and marketing rights from Ochoa Laboratories Limited (Ochoa) for its entire range of dermatological and lifestyle products. The acquired brands command considerable equity with doctors and are market leaders in their respective categories. They complement Ranbaxy’s existing derma portfolio. The products enjoy high margins because of their novelty and brand appeal and will be initially marketed in India. The current market size of the Dermatology segments in India is approximately Rs. 1950 crores, growing rapidly at about 11%. Ranbaxy already has a strong presence in the dermatology market including steroids with products such as Zole-F, Suncros, Efflora, Fucidin and Teczine, among others.
Source:Ranbaxy